Last reviewed · How we verify
Norethisterone,Ethinylestradiol
Norethisterone is a progestogen that acts as an agonist of the progesterone receptor, while ethinylestradiol is an estrogen that acts as an agonist of the estrogen receptor.
Norethisterone is a progestogen that acts as an agonist of the progesterone receptor, while ethinylestradiol is an estrogen that acts as an agonist of the estrogen receptor. Used for Contraception.
At a glance
| Generic name | Norethisterone,Ethinylestradiol |
|---|---|
| Sponsor | Nobelpharma |
| Drug class | progestogen-estrogen combination |
| Target | progesterone receptor, estrogen receptor |
| Modality | Small molecule |
| Therapeutic area | Women's Health |
| Phase | Phase 3 |
Mechanism of action
Norethisterone and ethinylestradiol work together to prevent ovulation and thicken cervical mucus, preventing sperm from reaching the egg. This combination of hormones is used in birth control pills to prevent pregnancy.
Approved indications
- Contraception
Common side effects
- Nausea
- Headache
- Breast tenderness
- Mood changes
Key clinical trials
- Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants (PHASE1)
- A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together (PHASE1)
- Relative Desirability of Metformin vs. Birth Control Pill in Treating PCOS in Women of Later Reproductive Age (EARLY_PHASE1)
- Ovulation Incidence in Oral Contraceptive Users (PHASE3)
- Effect of Evobrutinib on Pharmacokinetics of a Combined Oral Contraceptive (PHASE1)
- International Active Surveillance Study: Safety of Estrogen Estetrol (E4) Contraceptive Study (INAS-SEECS)
- Pharmacokinetics of NPC-01 After Single Oral Administration in Healthy Female Volunteers (PHASE3)
- Efficacy and Safety, Long-Term Study of NPC-01 to Treat Dysmenorrhea Associated With Endometriosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Norethisterone,Ethinylestradiol CI brief — competitive landscape report
- Norethisterone,Ethinylestradiol updates RSS · CI watch RSS
- Nobelpharma portfolio CI